JP2023540037A - ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 - Google Patents

ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 Download PDF

Info

Publication number
JP2023540037A
JP2023540037A JP2023513355A JP2023513355A JP2023540037A JP 2023540037 A JP2023540037 A JP 2023540037A JP 2023513355 A JP2023513355 A JP 2023513355A JP 2023513355 A JP2023513355 A JP 2023513355A JP 2023540037 A JP2023540037 A JP 2023540037A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
cov
amino acid
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540037A5 (enExample
Inventor
ゲボルグ グリゴリアン，
ジョン イングラハム，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー filed Critical フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー
Publication of JP2023540037A publication Critical patent/JP2023540037A/ja
Publication of JP2023540037A5 publication Critical patent/JP2023540037A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023513355A 2020-08-26 2021-08-26 ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 Pending JP2023540037A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070707P 2020-08-26 2020-08-26
US63/070,707 2020-08-26
PCT/US2021/047757 WO2022047033A1 (en) 2020-08-26 2021-08-26 Antigen binding molecules targeting sars-cov-2

Publications (2)

Publication Number Publication Date
JP2023540037A true JP2023540037A (ja) 2023-09-21
JP2023540037A5 JP2023540037A5 (enExample) 2024-08-26

Family

ID=77897739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513355A Pending JP2023540037A (ja) 2020-08-26 2021-08-26 ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子

Country Status (9)

Country Link
US (1) US11987616B2 (enExample)
EP (1) EP4204446A1 (enExample)
JP (1) JP2023540037A (enExample)
KR (1) KR20230058434A (enExample)
CN (1) CN116528897A (enExample)
AU (1) AU2021332340A1 (enExample)
CA (1) CA3188716A1 (enExample)
IL (1) IL300720A (enExample)
WO (1) WO2022047033A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010912A1 (en) 2020-07-06 2022-01-13 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CN116528897A (zh) 2020-08-26 2023-08-01 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
AR123469A1 (es) * 2020-09-10 2022-12-07 Bighat Biosciences Inc DOMINIOS DE UNIÓN A LA GLICOPROTEÍNA ESPICULAR DEL SARS-CoV(-2) Y POLIPÉPTIDOS QUE LOS COMPRENDEN Y USO DE ESTOS
EP4519310A1 (en) 2022-05-06 2025-03-12 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
WO2024102674A1 (en) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
CN117442594A (zh) * 2023-04-20 2024-01-26 厦门大学 化合物在诊断与治疗新型冠状病毒感染中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
CA2548942C (en) 2003-12-05 2013-10-15 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
UA119328C2 (uk) 2013-08-09 2019-06-10 Астеллас Фарма Інк. Антитіло до тslp-рецептора людини
CN108064243B (zh) 2014-10-01 2021-08-27 免疫医疗有限公司 对lox1具有特异性的结合蛋白及其用途
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
WO2020180398A1 (en) 2019-01-14 2020-09-10 The Regents Of The University Of California Compositions and methods for modulating cellular internalization
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
WO2021156490A2 (en) * 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
EP4121454A1 (en) 2020-03-19 2023-01-25 Imperial College Innovations Limited Coronavirus antibody
US11028167B1 (en) 2020-03-23 2021-06-08 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 3bgf
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
US20230348571A1 (en) 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
JP2023521418A (ja) 2020-04-10 2023-05-24 インビビド， インコーポレイテッド コロナウイルスｓタンパク質に特異的な化合物及びその使用
US20240059757A1 (en) 2020-04-14 2024-02-22 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
US20230174628A1 (en) 2020-04-28 2023-06-08 Peking University Anti-novel coronavirus monoclonal antibody and application thereof
WO2021226560A1 (en) 2020-05-08 2021-11-11 Vir Biotechnology, Inc. Antibodies against sars-cov-2
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
WO2022010912A1 (en) 2020-07-06 2022-01-13 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
WO2022015573A2 (en) 2020-07-13 2022-01-20 President And Fellows Of Harvard College Sars-cov-2 antigen-binding proteins and uses thereof
WO2022026475A2 (en) 2020-07-27 2022-02-03 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use
CN116528897A (zh) 2020-08-26 2023-08-01 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
KR20230127305A (ko) 2020-12-29 2023-08-31 발-첨, 리미티드 파트너십 Covid-19에 대한 중화 단일클론 항체
WO2022159685A2 (en) 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
KR20240035758A (ko) 2021-05-24 2024-03-18 비르 바이오테크놀로지, 인코포레이티드 조작된 폴리펩타이드
WO2022271863A1 (en) 2021-06-23 2022-12-29 Chan Zuckerberg Biohub, Inc. Coronavirus neutralizing compositions and associated methods
WO2023028603A2 (en) 2021-08-27 2023-03-02 Humabs Biomed Sa Engineered compositions
EP4147716A1 (en) 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
EP4519310A1 (en) 2022-05-06 2025-03-12 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACCESSION NO. MT350284.1, GENBANK [ONLINE], vol. [検索日 2025.07.29], JPN6025031641, May 2020 (2020-05-01), ISSN: 0005783698 *
DANIEL WRAPP ET AL., CELL, vol. 181, no. 5, JPN6025031640, May 2020 (2020-05-01), pages 1005 - 1015, ISSN: 0005783697 *

Also Published As

Publication number Publication date
CA3188716A1 (en) 2022-03-03
EP4204446A1 (en) 2023-07-05
WO2022047033A1 (en) 2022-03-03
AU2021332340A9 (en) 2024-05-09
AU2021332340A1 (en) 2023-10-05
KR20230058434A (ko) 2023-05-03
IL300720A (en) 2023-04-01
CN116528897A (zh) 2023-08-01
US11987616B2 (en) 2024-05-21
US20230287089A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
US11987616B2 (en) Antigen binding molecules targeting SARS-CoV-2
US11981725B2 (en) Antigen binding molecules targeting SARS-CoV-2
WO2021244089A1 (zh) 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用
US12473560B2 (en) Antigen binding molecules targeting SARS-CoV-2
KR102748987B1 (ko) 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도
EP3970798A1 (en) Sars-cov-2-nanobodies
US20240398911A1 (en) Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof
CN110612310B (zh) 抗cldn-5抗体及含有该抗体的药物
CN116547005A (zh) 靶向SARS-CoV-2的抗原结合分子
CN118812704B (zh) 一种抗新型冠状病毒的四价中和抗体及其应用
CN116635410A (zh) 靶向SARS-CoV-2的抗原结合分子
US20240043506A1 (en) Sars-cov-2 antibodies
US11174322B2 (en) Antibodies and peptides to treat HCMV related diseases
WO2025230768A1 (en) Compositions and methods related to coronavirus therapies
IL325269A (en) Antibodies specific for MHC class I chain-associated protein A (MICA) and their uses
TW202309069A (zh) 糖鏈修飾rbd及其用途
CN121773139A (zh) 抗c-MET纳米抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260408